CEACAM7 Antibody | 58-984

CEACAM7 Antibody | 58-984 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: This CEACAM7 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 112-140 amino acids from the Central region of human CEACAM7.

Research Area: Other

Tested Application: WB, IHC-P

Application: For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:10~50

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: 29 kDa

Validation: N/A

Isoform: N/A

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Clonality: Polyclonal

Clone: N/A

Isotype: Rabbit Ig

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Supplied in PBS with 0.09% (W/V) sodium azide.

Concentration: batch dependent

Storage Condition: Store at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Carcinoembryonic antigen-related cell adhesion molecule 7, Carcinoembryonic antigen CGM2, CEACAM7, CGM2

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CEA-related cell adhesion molecule 7 (CEACAM7, CGM2) belongs to the carcinoembryonic antigen (CEA) family. It encodes a glycosyl phosphatidyl inositol (GPI) -linked glycoprotein which is only found on the apical surface of highly differentiated epithelial cells adult colon and on a small epithelial cell population in pancreatic ducts. CEACAM7 expression is completely lost upon malignant transformation already in hyperplastic polyps and early adenomas as well as in adenocarcinomas of the colon. Like all members of the CEACAM family, it consists of a single N domain, with structural homology to the immunoglobulin variable domains, followed by one immunoglobulin constantlike A domain.